SEED Capital Denmark and other private investors have invested in Valderm, a Danish pharmaceutical company which specialises in developing psoriasis treatment. The company's product is still in its pre-clinical trial stage, but is expected to be on the market in a few years.
Calucem reports a turnover of EUR 58m, with an EBITDA of EUR 16m
Should Apex make a firm offer, Cinven would have to significantly up its own bid for the fund administrator
Third exit announced by Lonsdale this year, and the second from its 2016 fund
Paris-based private equity firm is exploring options around a dual-track process